Date: Mon-	ch 10, 2023
Your Name:	_ Ting Li
Manuscript Title:	A Phase II Study of anlotinib with the third-generation EGFR tyrosine kinase inhibitors in
	tant patients with advanced NSCLC
Manuscript number	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	k

13	Other financial or non- financial interests	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	None	
11	Stock or stock options	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
8	Patents planned, issued or pending	None	
7	Support for attending meetings and/or travel	None	
6	Payment for expert testimony	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	

I have more of the above conflict of interest with any entity or individual.

Please place an "X" next to the following statement to indicate your agreement:

Date: March	10-2023
Your Name:	Kejie Chang
Manuscript Title:_ EGFR-mutant patie	A Phase II Study of anlotinib with the third-generation EGFR tyrosine kinase inhibitors in untreated nts with advanced NSCLC
Manuscript numbe	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	100000000000000000000000000000000000000	Time frame: pas	tt 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I have none of the	above	conflict	of	interest	with	any	entity
or individual							

Please place an "X" next to the following statement to indicate your agreement:

Date: March	(V, Z)Z)
Your Name:	_Xin Qiu
Manuscript Title:	A Phase II Study of anIotinib with the third-generation EGFR tyrosine kinase inhibitors in untreated
	nts with advanced NSCLC
Manuscript number	(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
9239		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	The second secon	Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,	17 None	
	manuscript writing or educational events		
	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
5	pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I have none of the above conflict of interest with any entity or individual.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March 10 2023
Your Name:	Zhirong Lai
Manuscript Title:_	A Phase II Study of aniotinib with the third-generation EGFR tyrosine kinase inhibitors in untreated
	ents with advanced NSCLC
Manuscript number	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>✓_None</u>	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	1774 2 1874 1874 1874 1874 1874 1874 1874 1874
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	None	

5	Payment or honoraria for	✓ None	
	lectures, presentations, speakers bureaus,	None	
			Provided to the control of the contr
	manuscript writing or		AND AND ASSESSMENT OF A STATE OF
	educational events		
6	Payment for expert	✓ None	
	testimony		
7	Company to the state of		
'	Support for attending meetings and/or travel	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data Safety Monitoring Board or	None	
		APPLIANCE STORY OF STREET	
4.0	Advisory Board		Description of the second seco
10	Leadership or fiduciary role	None	
	in other board, society,		
	group, paid or unpaid	Control of the Control of the	Programme and the second of th
11	Stock or stock options	None	
	Stock of Stock options	None	
12		Control of the second	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other	199	
	services		
13	Other financial or non-	None	
	financial interests		TO BE A STORE OF THE STORE OF T

I have none of the above conflict of interest with any entity or individual.

Please place an "X" next to the following statement to indicate your agreement:

Date: March	10. 2023
Your Name:	Yuanling Luo
Manuscript Title:	A Phase II Study of anIotinib with the third-generation EGFR tyrosine kinase inhibitors in untreated
EGFR-mutant paties	nts with advanced NSCLC
Manuscript number	r (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	at 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
1	Consulting fees	None	

ayment or honoraria for ectures, presentations, peakers bureaus, nanuscript writing or ducational events ayment for expert estimony upport for attending neetings and/or travel	NoneNoneNone		
peakers bureaus, nanuscript writing or ducational events ayment for expert estimony upport for attending	None		
nanuscript writing or ducational events ayment for expert estimony	None		
ducational events ayment for expert estimony upport for attending	None		
ayment for expert estimony upport for attending	None		
estimony upport for attending	None		
upport for attending	None		
	None		
	None		
rectiligs allu/of travel			
Intents planned issued as	√None		
Patents planned, issued or pending	None		
renung			
Participation on a Data Safety Monitoring Board or	√ None		
Advisory Board	4.		e e construir de la construir
Leadership or fiduciary role in other board, society,	√ None		
committee or advocacy			
roup, paid or unpaid		Table, a series de la companya della companya de la companya della	
tock or stock options	None		
localist of acultument	None		
Receipt of equipment,	None		
writing gifts or other			
vriting, gifts or other ervices	1 None		
vriting, gifts or other ervices Other financial or non-	I V NUIC		
	vices	ting, gifts or other vices ner financial or nonNone	ting, gifts or other vices

I have none of the above conflict of interest with any entity or individual.

Please place an "X" next to the following statement to indicate your agreement:

Date: Maro	h 10. 2023
Your Name:	Jiagun Chen
Manuscript Title:_	A Phase II Study of aniotinib with the third-generation EGFR tyrosine kinase inhibitors in untreate
	ents with advanced NSCLC
Manuscript numb	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Vone	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u>√</u> None	
6	Payment for expert testimony	<u>✓</u> None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	<u>V</u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>V</u> None	
13	Other financial or non- financial interests	None	

I have none of the above conflict of interest with any entity or individual.

Please place an "X" next to the following statement to indicate your agreement:

Date: March	10.2025
Your Name:	Weize Ly
	A Phase II Study of anlotinib with the third-generation EGFR tyrosine kinase inhibitors in untreated
	its with advanced NSCLC
Manuscript number	(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
160		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	Vone	And Discourse Control of Bengins (Control of the Control of the Co
	lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	None	
7		,	
′	Support for attending	None	
	meetings and/or travel		COUNTY OF PARK TO THE PARK THE PARK THE TEXT OF THE PARK THE TEXT OF THE PARK THE PA
		· 多种种种种种种种种种种种种种种种种种种种种种种种种种种种种种种种种种种种种	
8	Patents planned, issued or	None	
	pending	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
	Stock of Stock options	None	
12	Receipt of equipment,	<u>✓_</u> None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

1 have	none	of the above	conflict	of interest
with any	entity	or individual		nillion

Please place an "X" next to the following statement to indicate your agreement:

Date: March	10.2027
Your Name:	Zhong Lin
Manuscript Title:	A Phase II Study of anIotinib with the third-generation EGFR tyrosine kinase inhibitors in untreated
	nts with advanced NSCLC
Manuscript numbe	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None			
		Time frame: pas	at 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None			
3	Royalties or licenses	None			
4	Consulting fees	None			

Payment or honoraria for lectures, presentations,	None	
speakers bureaus,		
manuscript writing or		and the second of the second o
educational events		
Payment for expert	√ None	
testimony		
Company (. /	
	None	The state of the s
meetings and/or traver		
Patents planned, issued or	✓ None	
pending		
B		
Safety Monitoring Board or	None	
	✓ None	
in other board, society,		, and a second s
committee or advocacy		
Stock or stock options	<u></u> ✓ None	
Receipt of equipment,	None	
materials, drugs, medical		
	1	
	None	
	Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment,	Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- None

Please place an "X" next to the following statement to indicate your agreement:

Date: Nav	ch 10,2023
Your Name:	Xiaofeng Pei
Manuscript Title:_	A Phase II Study of aniotinib with the third-generation EGFR tyrosine kinase inhibitors in untreated
EGFR-mutant patie	nts with advanced NSCLC
Manuscript number	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1 all		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
	The second secon	Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	__None	
3	Royalties or licenses	None	
4	Consulting fees	<u></u> ✓None	

5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>√</u> None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I have none of the above any entity or individual.	conflict of inserest with
and every	

Please place an "X" next to the following statement to indicate your agreement:

Date: March	10 2013	
Your Name:	Xiangwen Wu	
Manuscript Title	Alangwen wu	f anlotinib with the third-generation EGFR tyrosine kinase inhibitors in untreated
	ents with advanced	VSCLC
Manuscript number	er (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
507		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Mario S	A CONTRACTOR OF THE STATE OF TH	Time frame: pas	at 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

		1	
5	Payment or honoraria for lectures, presentations, speakers bureaus,	<u>√</u> None	
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I have none of the above conflict of interest with any entity or individual.

Please place an "X" next to the following statement to indicate your agreement:

	arch 10.2023	
Your Name:	Xiaojin Wang	
Manuscript Title:_	_ A Phase II Study of anlotinib with the third-generation EGFR tyrosine kinase inhibitors in untrea	ed
EGFR-mutant patie	ents with advanced NSCLC	
Manuscript number		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1800		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Daymant as bases of	1/	
	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	AND
	testimony	None	
7	Support for attending	None	
	meetings and/or travel		
		CONTRACTOR OF THE REP	14 1000 (1000 1000 1000 1000 1000 1000 1
8	Patents planned, issued or pending	None	
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
		Lagrange Company	
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		The second secon

I have none of the above conflict of interest with any entity or individual.

Please place an "X" next to the following statement to indicate your agreement: